



Making Science work for you...

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2009

[Rs. in Lacs]

[Rs. in Lacs]

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended December 31 (Unaudited)	Nine Months Ended December 31 (Unaudited)	Year Ended March 31 (Audited)				Quarter Ended December 31 (Unaudited)	Nine Months Ended December 31 (Unaudited)	Year Ended March 31 (Audited)		
2009	2008	2009	2008	2009		2009	2008	2009	2008	2009
96148	90964	279095	267674	351798	Net sales/Income from operations	61249	58741	184579	188266	243072
490	1124	1340	2191	2434	Other Operating Income	344	220	972	1009	1138
96638	92088	280435	269865	354232	Total income	61593	58961	185551	189275	244210
76765	81198	231409	231071	310893	Total expenditure	46929	50389	142712	153375	208352
845	(445)	2071	(5945)	(7813)	a) (Increase)/Decrease in stock in trade and work in progress	340	(1032)	1947	(5105)	(2811)
4927	2743	13606	8931	11349	b) Purchase of traded goods	4739	2652	12760	7329	10668
31015	34325	93756	102350	131488	c) Raw & process materials consumed	26374	29188	77828	89666	113470
5955	4838	16905	16102	21116	d) Stores, spares, chemicals, catalyst & packing material consumed	2945	2611	8257	9314	11666
5881	4360	16409	15909	19791	e) Power & fuel	5352	3894	14949	14617	18079
2064	2380	5084	6473	8675	f) Other manufacturing expenses	1337	1365	3803	4622	6364
18880	18249	56048	47969	65749	g) Staff cost	4799	4476	13321	11916	15600
3125	4343	9284	11815	16324	h) Depreciation	1657	1935	4842	5368	7462
4073	10405	18246	27467	44214	i) Selling, general & admin. Expenses (Including Exchange Loss/Gain)	(614)	5300	5005	15648	27854
19873	10890	49026	38794	43339	Operating profit before Other Income & Interest	14664	8572	42839	35900	35858
790	408	1576	789	1816	Other Income	409	141	877	268	674
20663	11298	50602	39583	45155	Profit before Interest & Exceptional Items	15073	8713	43716	36168	36532
3899	3239	11600	6821	10704	Interest (Net)	2695	1394	8174	2713	5435
16764	8059	39002	32762	34451	Profit after Interest but before Exceptional Items	12378	7319	35542	33455	31097
4082	14239	3455	42417	4793	Exceptional items	3914	7106	2279	32290	3794
12682	(6180)	35547	(9655)	29658	Profit from Ordinary Activities before tax	8464	213	33263	1165	27303
2253	2825	6883	5098	2672	Tax Expenses (Net)	1407	2329	6154	4269	1229
10429	(9005)	28664	(14753)	26986	Net profit from Ordinary Activities after tax	7057	(2116)	27109	(3104)	26074
-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-
349	(248)	234	(1000)	(1332)	Minority Interest	-	-	-	-	-
10080	(8757)	28430	(13753)	28318	Net profit after Minority Interest	7057	(2116)	27109	(3104)	26074
1475	1475	1475	1475	1475	Paid-up share capital (Face value per share Re.1)	1475	1475	1475	1475	1475
				125279	Reserves (excluding revaluation reserve)					132463
6.83	(5.95)	19.27	(9.34)	19.22	Earnings per share before and after extraordinary items (Not annualized)	4.78	(1.44)	18.37	(2.11)	17.70
5.89	(4.93)	16.63	(7.74)	16.56	Basic (Rs.)	4.13	(1.19)	15.86	(1.75)	15.25
					Diluted (Rs.)					
					Public shareholding					
72565234	73164234	72565234	73164234	73121834	- Number of shares (Re. 1 each)	72565234	73164234	72565234	73164234	73121834
49.18	49.59	49.18	49.59	49.56	- Percentage of shareholding	49.18	49.59	49.18	49.59	49.56
					Promoters and promoter group Shareholding					
					a) Pledged/Encumbered					
14245000		14245000		16421000	- Number of shares	14245000		14245000		16421000
19.00		19.00		22.07	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	19.00		19.00		22.07
9.66		9.66		11.13	- Percentage of shares (as a % of the total share capital of the company)	9.66		9.66		11.13
					b) Non-Encumbered					
60732024		60732024		57999424	- Number of shares	60732024		60732024		57999424
81.00		81.00		77.93	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	81.00		81.00		77.93
41.16		41.16		39.31	- Percentage of shares (as a % of the total share capital of the company)	41.16		41.16		39.31

Segment wise Revenue, Results & Capital Employed (under Clause 41 of the Listing Agreement)										
CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
Quarter Ended December 31 (Unaudited)	Nine Months Ended December 31 (Unaudited)	Year Ended March 31 (Audited)				Quarter Ended December 31 (Unaudited)	Nine Months Ended December 31 (Unaudited)	Year Ended March 31 (Audited)		
2009	2008	2009	2008	2009		2009	2008	2009	2008	2009
85957	76011	246781	222944	297545	Segment revenue	51082	43546	152353	143252	188794
10324	15007	32680	45050	54651	a. Pharmaceuticals and Life Sciences Products & Services	10300	15249	32592	45334	54676
96281	91018	279461	267994	352196	b. Agri & Performance Polymers	61382	58795	184945	188586	243470
133	54	366	320	398	Total	133	54	366	320	398
96148	90964	279095	267674	351798	Net sales/Income from operations	61249	58741	184579	188266	243072
85824	75957	246415	222624	297147	a. Pharmaceuticals and Life Sciences Products & Services	50949	43492	151987	142932	188396
10324	15007	32680	45050	54651	b. Agri & Performance Polymers	10300	15249	32592	45334	54676
96148	90964	279095	267674	351798	Total	61249	58741	184579	188266	243072
21225	12686	54693	39213	49186	Segment results (profit+)/loss(-) before tax and interest from each segment	15641	10021	47813	35887	40660
875	498	887	3967	3968	a. Pharmaceuticals and Life Sciences Products & Services	870	590	882	4067	4073
22100	13184	55580	43180	53154	b. Agri & Performance Polymers	16511	10611	48695	39954	44733
3899	3239	11600	6821	10704	Total	2695	1394	8174	2713	5435
1900	16292	10494	46547	19636	Less : i Interest	2002	9157	9319	36357	18577
3619	(167)	(2061)	(533)	(6844)	ii. Other un-allocable expenditure (including exceptional items)	3350	(153)	(2061)	(281)	(6582)
12682	(6180)	35547	(9655)	29658	iii. Un-allocable Income (including exceptional items)	8464	213	33263	1165	27303
474195	456343	474195	456343	465462	Capital Employed (Segment assets less Segment liabilities)	179294	185753	179294	185753	183306
16502	21014	16502	21014	19061	a. Pharmaceuticals and Life Sciences Products & Services	16249	20534	16249	20534	18815
490697	477357	490697	477357	484523	b. Agri & Performance Polymers	195543	206287	195543	206287	202121
24770	50148	24770	50148	44744	Total Capital employed in segments	192154	198309	192154	198309	197037
515467	527505	515467	527505	529267	Add: Un-allocable corporate assets less liabilities	387697	404596	387697	404596	399158

Notes:

- In line with the continued strategy to make the company a focused Pharma and Life Sciences Company, the Board has in principle approved business restructuring involving demerger of Agri and Performance Polymers business into a separate company. Accordingly the reporting segments have been redefined as Pharmaceuticals and Life Sciences Products and Services (PLSPS) and Agri & Performance Polymers (APP) to reflect the results of these two businesses separately. The demerger will be carried out through a court scheme and is subject to necessary regulatory and other approvals/sanctions.
- The company had opted for accounting of exchange difference arising on reporting of long term monetary items under AS 11 in line with the Companies (Accounting Standard) Amendment Rules 2009 in quarter ending March 2009 for the entire financial year 2008-09. Accordingly the said exchange loss in previous year amounting to Rs 5958 Lacs (Consolidated Rs. 13091 Lacs) for Q3-FY 2009 and Rs.30700 Lacs (Consolidated Rs. 40827 Lacs) for 9M-FY 2009 has been recast to fixed assets / foreign currency monetary items translation difference account (FCMITDA) at the year end. The balance in FCMITDA amounting to Rs.3601 Lacs (Consolidated Rs.5272 Lacs) subject to further fluctuations on reporting date shall be amortised till March 2011.
- In order to bring uniformity in accounting policy, beginning 1st April 2009, the depreciation method, in respect of certain assets has been changed from written down value method to straight line method with retrospective effect as per AS 6 and consequent effect is a cumulative lower depreciation charge by Rs 3117 Lacs (Consolidated Rs 6603 Lacs). A pro-rata amount has been reduced from current period depreciation charge amounting to Rs 779 Lacs (Consolidated Rs 1651 Lacs) for Q3-FY 2010 and Rs 2337 Lacs (Consolidated Rs. 4953 Lacs) for 9M-FY 2010. Due to effect of such change in policy, the depreciation charge in the current period is also lower by Rs 89 Lacs (Consolidated Rs. 182 Lacs) for the Q3-FY 2010 and Rs 266 Lacs (consolidated - Rs 475 Lacs) for 9M-FY 2010.
- Exceptional items include :
i) Amortisation of Foreign Currency Monetary item Translation Difference Account, Rs.- 220 Lacs (Consolidated Rs.- 320 Lacs) for Q3-FY 2010 and Rs.2408 Lacs (Consolidated Rs. 3387 Lacs) for 9M-FY 2010.
ii) Movement in Mark to Market(MTM) of unassigned forward contracts/interest rate swap outstanding at the period end resulting in Loss amounting to Rs 4134 Lacs (Consolidated loss amounting to Rs. 4402 Lacs) for Q3-FY 2010 and gain amounting to Rs. 129 Lacs (Consolidated - loss amounting to Rs.68 Lacs) for 9M-FY 2010.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New 45, Disposals 45, Closing Balance - Nil.
- Previous year / periods figures have been regrouped/reclassified wherever necessary.
- The above un-audited results were subjected to limited review by the auditors of the company and were approved by the Board of Directors at its meeting held on 21st January, 2010.

For Jubilant Organosys Ltd.

Place : Noida
Dated : 21st January, 2010

Shyam S Bhartia
Chairman & Managing Director

visit us at www.jubl.com